Although selective CDK4/6 inhibition results in less toxicity, a huge challenge is that breast cancer (including basal-like breast cancer) adapt quickly to CDK4/6 inhibition, while inhibiting CDK2 simultaneously is an effective solution [38, 39]. Here, CDK4 is linked to breast cancer.